Standard
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) : a randomised, open-label, multicentre, phase 3 trial. / Powles, Thomas; Van Der Heijden, Michiel S.; Castellano, Daniel; Galsky, Matthew D; Loriot, Yohann; Petrylak, Daniel P; Ogawa, Osamu; Park, Se Hoon; Lee, Jae-lyun; De Giorgi, Ugo; Bögemann, Martin; Bamias, Aristotelis; Eigl, Bernhard J; Gurney, Howard; Mukherjee, Som D; Fradet, Yves; Skoneczna, Iwona; Tsiatas, Marinos; Novikov, Andrey; Suárez, Cristina; Fay, André P; Duran, Ignacio; Necchi, Andrea; Wildsmith, Sophie; He, Philip; Angra, Natasha; Gupta, Ashok K; Levin, Wendy; Bellmunt, Joaquim; Park, Se Hoon; Van Der Heijden, Michiel S.; Necchi, Andrea; Castellano, Daniel; Bamias, Aristotelis; Lee, Jae Lyun; De Giorgi, Ugo; Bögemann, Martin; Eigl, Bernhard J.; Tsiatas, Marinos; Powles, Thomas; Novikov, Andrey; Skoneczna, Iwona; Mukherjee, Som D.; Suarez, Cristina; Westgeest, Hans; Fradet, Yves; Flechon, Aude; Ou, Yen-chuan; Pappot, Helle; Sengelov, Lisa; DANUBE study investigators.
I:
The Lancet Oncology, Bind 21, Nr. 12, 01.12.2020, s. 1574-1588.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Powles, T, Van Der Heijden, MS, Castellano, D, Galsky, MD, Loriot, Y, Petrylak, DP, Ogawa, O, Park, SH, Lee, J, De Giorgi, U, Bögemann, M, Bamias, A, Eigl, BJ, Gurney, H, Mukherjee, SD, Fradet, Y, Skoneczna, I, Tsiatas, M, Novikov, A, Suárez, C, Fay, AP, Duran, I, Necchi, A, Wildsmith, S, He, P, Angra, N, Gupta, AK, Levin, W, Bellmunt, J, Park, SH, Van Der Heijden, MS, Necchi, A, Castellano, D, Bamias, A, Lee, JL, De Giorgi, U, Bögemann, M, Eigl, BJ, Tsiatas, M, Powles, T, Novikov, A, Skoneczna, I, Mukherjee, SD, Suarez, C, Westgeest, H, Fradet, Y, Flechon, A, Ou, Y
, Pappot, H, Sengelov, L & DANUBE study investigators 2020, '
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial',
The Lancet Oncology, bind 21, nr. 12, s. 1574-1588.
https://doi.org/10.1016/S1470-2045(20)30541-6APA
Powles, T., Van Der Heijden, M. S., Castellano, D., Galsky, M. D., Loriot, Y., Petrylak, D. P., Ogawa, O., Park, S. H., Lee, J., De Giorgi, U., Bögemann, M., Bamias, A., Eigl, B. J., Gurney, H., Mukherjee, S. D., Fradet, Y., Skoneczna, I., Tsiatas, M., Novikov, A., ... DANUBE study investigators (2020).
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
The Lancet Oncology,
21(12), 1574-1588.
https://doi.org/10.1016/S1470-2045(20)30541-6Vancouver
Powles T, Van Der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP o.a.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
The Lancet Oncology. 2020 dec. 1;21(12):1574-1588.
https://doi.org/10.1016/S1470-2045(20)30541-6Author
Powles, Thomas ; Van Der Heijden, Michiel S. ; Castellano, Daniel ; Galsky, Matthew D ; Loriot, Yohann ; Petrylak, Daniel P ; Ogawa, Osamu ; Park, Se Hoon ; Lee, Jae-lyun ; De Giorgi, Ugo ; Bögemann, Martin ; Bamias, Aristotelis ; Eigl, Bernhard J ; Gurney, Howard ; Mukherjee, Som D ; Fradet, Yves ; Skoneczna, Iwona ; Tsiatas, Marinos ; Novikov, Andrey ; Suárez, Cristina ; Fay, André P ; Duran, Ignacio ; Necchi, Andrea ; Wildsmith, Sophie ; He, Philip ; Angra, Natasha ; Gupta, Ashok K ; Levin, Wendy ; Bellmunt, Joaquim ; Park, Se Hoon ; Van Der Heijden, Michiel S. ; Necchi, Andrea ; Castellano, Daniel ; Bamias, Aristotelis ; Lee, Jae Lyun ; De Giorgi, Ugo ; Bögemann, Martin ; Eigl, Bernhard J. ; Tsiatas, Marinos ; Powles, Thomas ; Novikov, Andrey ; Skoneczna, Iwona ; Mukherjee, Som D. ; Suarez, Cristina ; Westgeest, Hans ; Fradet, Yves ; Flechon, Aude ; Ou, Yen-chuan ; Pappot, Helle ; Sengelov, Lisa ; DANUBE study investigators. / Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) : a randomised, open-label, multicentre, phase 3 trial. I: The Lancet Oncology. 2020 ; Bind 21, Nr. 12. s. 1574-1588.
Bibtex
@article{8ab4ebba46754849bd8b3218a6583f37,
title = "Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial",
author = "Thomas Powles and {Van Der Heijden}, {Michiel S.} and Daniel Castellano and Galsky, {Matthew D} and Yohann Loriot and Petrylak, {Daniel P} and Osamu Ogawa and Park, {Se Hoon} and Jae-lyun Lee and {De Giorgi}, Ugo and Martin B{\"o}gemann and Aristotelis Bamias and Eigl, {Bernhard J} and Howard Gurney and Mukherjee, {Som D} and Yves Fradet and Iwona Skoneczna and Marinos Tsiatas and Andrey Novikov and Cristina Su{\'a}rez and Fay, {Andr{\'e} P} and Ignacio Duran and Andrea Necchi and Sophie Wildsmith and Philip He and Natasha Angra and Gupta, {Ashok K} and Wendy Levin and Joaquim Bellmunt and Park, {Se Hoon} and {Van Der Heijden}, {Michiel S.} and Andrea Necchi and Daniel Castellano and Aristotelis Bamias and Lee, {Jae Lyun} and {De Giorgi}, Ugo and Martin B{\"o}gemann and Eigl, {Bernhard J.} and Marinos Tsiatas and Thomas Powles and Andrey Novikov and Iwona Skoneczna and Mukherjee, {Som D.} and Cristina Suarez and Hans Westgeest and Yves Fradet and Aude Flechon and Yen-chuan Ou and Helle Pappot and Lisa Sengelov and {DANUBE study investigators}",
year = "2020",
month = dec,
day = "1",
doi = "10.1016/S1470-2045(20)30541-6",
language = "English",
volume = "21",
pages = "1574--1588",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "TheLancet Publishing Group",
number = "12",
}
RIS
TY - JOUR
T1 - Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
T2 - a randomised, open-label, multicentre, phase 3 trial
AU - Powles, Thomas
AU - Van Der Heijden, Michiel S.
AU - Castellano, Daniel
AU - Galsky, Matthew D
AU - Loriot, Yohann
AU - Petrylak, Daniel P
AU - Ogawa, Osamu
AU - Park, Se Hoon
AU - Lee, Jae-lyun
AU - De Giorgi, Ugo
AU - Bögemann, Martin
AU - Bamias, Aristotelis
AU - Eigl, Bernhard J
AU - Gurney, Howard
AU - Mukherjee, Som D
AU - Fradet, Yves
AU - Skoneczna, Iwona
AU - Tsiatas, Marinos
AU - Novikov, Andrey
AU - Suárez, Cristina
AU - Fay, André P
AU - Duran, Ignacio
AU - Necchi, Andrea
AU - Wildsmith, Sophie
AU - He, Philip
AU - Angra, Natasha
AU - Gupta, Ashok K
AU - Levin, Wendy
AU - Bellmunt, Joaquim
AU - Park, Se Hoon
AU - Van Der Heijden, Michiel S.
AU - Necchi, Andrea
AU - Castellano, Daniel
AU - Bamias, Aristotelis
AU - Lee, Jae Lyun
AU - De Giorgi, Ugo
AU - Bögemann, Martin
AU - Eigl, Bernhard J.
AU - Tsiatas, Marinos
AU - Powles, Thomas
AU - Novikov, Andrey
AU - Skoneczna, Iwona
AU - Mukherjee, Som D.
AU - Suarez, Cristina
AU - Westgeest, Hans
AU - Fradet, Yves
AU - Flechon, Aude
AU - Ou, Yen-chuan
AU - Pappot, Helle
AU - Sengelov, Lisa
AU - DANUBE study investigators
PY - 2020/12/1
Y1 - 2020/12/1
U2 - 10.1016/S1470-2045(20)30541-6
DO - 10.1016/S1470-2045(20)30541-6
M3 - Journal article
VL - 21
SP - 1574
EP - 1588
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 12
ER -
